Follow
Alex Matter
Alex Matter
CEO, AtumRa Therapeutics Pte Ltd., Singapore
Verified email at atumratx.com
Title
Cited by
Cited by
Year
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
R Capdeville, E Buchdunger, J Zimmermann, A Matter
Nature reviews Drug discovery 1 (7), 493-502, 2002
18792002
A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and In vitro anti‐proliferative as well as In vivo anti‐tumor activity
T Meyer, U Regenass, D Fabbro, E Alteri, J Röusel, M Möller, G Caravatti, ...
International journal of cancer 43 (5), 851-856, 1989
5561989
Wnt addiction of genetically defined cancers reversed by PORCN inhibition
B Madan, Z Ke, N Harmston, SY Ho, AO Frois, J Alam, DA Jeyaraj, ...
Oncogene 35 (17), 2197-2207, 2016
3222016
Markers of tumor angiogenesis and proteolysis independently define high-and low-risk subsets of node-negative breast cancer patients.
U Eppenberger, W Kueng, JM Schlaeppi, JL Roesel, C Benz, H Mueller, ...
Journal of clinical oncology 16 (9), 3129-3136, 1998
2781998
Tumor angiogenesis as a therapeutic target
A Matter
Drug Discovery Today 6 (19), 1005-1024, 2001
1952001
Homo-and heterocellular junctions in cell cultures: an electrophysiological and morphological study
A Hyde, B Blondel, A Matter, JP Cheneval, B Filloux, L Girardier
Progress in brain research 31, 283-311, 1969
1801969
MOUSE THYMUS-INDEPENDENT AND THYMUS-DERIVED LYMPHOID CELLS: I. IMMUNOFLUORESCENT AND FUNCTIONAL STUDIES
JP Lamelin, B Lisowska-Bernstein, A Matter, JE Ryser, P Vassalli
The Journal of Experimental Medicine 136 (5), 984-1007, 1972
1751972
Microcinematographic and electron microscopic analysis of target cell lysis induced by cytotoxic T lymphocytes.
A Matter
Immunology 36 (2), 179, 1979
1721979
Protein tyrosine kinase inhibitors: new treatment modalities?
D Fabbro, D Parkinson, A Matter
Current Opinion in Pharmacology 2 (4), 374-381, 2002
1662002
A study on permeability barriers between Disse space and bile canaliculus
A Matter
J. Ultrastruct. Res. 1, 1969
1631969
Bcr-Abl inhibition as a modality of CML therapeutics.
E Buchdunger, A Matter, BJ Druker
Biochimica et Biophysica Acta 1551 (1), M11-8, 2001
1552001
From vitamin A to retinoids in experimental and clinical oncology: achievements, failures, and outlook
W Bollag, A Matter
Annals of the New York Academy of Sciences 359 (1), 9-23, 1981
1551981
Rescue of oxytocin response and social behaviour in a mouse model of autism
H Hörnberg, E Pérez-Garci, D Schreiner, L Hatstatt-Burklé, F Magara, ...
Nature 584 (7820), 252-256, 2020
1202020
CGS 16949A, a New Nonsteroidal Aromatase Inhibitor: Effects on Hormone-dependent and -independent Tumors in Vivo
K Schieweck, AS Bhatnagar, A Matter
Cancer research 48 (4), 834-838, 1988
1201988
Liver‐colonizing melanoma cells selected from B‐16 melanoma
TW Tao, A Matter, K Vogel, MM Burger
International Journal of Cancer 23 (6), 854-857, 1979
1181979
Anti‐tumor effects of tumor necrosis factor in combination with chemotherapeutic agents
U Regenass, M Müller, E Curschellas, A Matter
International journal of cancer 39 (2), 266-273, 1987
1021987
MOUSE THYMUS-INDEPENDENT AND THYMUS-DERIVED LYMPHOID CELLS: II. ULTRASTRUCTURAL STUDIES
A Matter, B Lisowska-Bernstein, JE Ryser, JP Lamelin, P Vassalli
The Journal of Experimental Medicine 136 (5), 1008-1030, 1972
991972
A morphometric study on the nexus of rat cardiac muscle
A Matter
The Journal of Cell Biology 56 (3), 690-696, 1973
831973
New S-Adenosylmethionine Decarboxylase Inhibitors with Potent Antitumor Activity
U Regenass, G Caravatti, H Mett, J Stanek, P Schneider, M Müller, ...
Cancer research 52 (17), 4712-4718, 1992
811992
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian …
JGH Low, LS Lee, EE Ooi, K Ethirajulu, P Yeo, A Matter, JE Connolly, ...
Vaccine 32 (39), 5041-5048, 2014
792014
The system can't perform the operation now. Try again later.
Articles 1–20